Kamada Q3 2026 earnings

KMDA · 2026-11-02 07:00 BMO ET · 6-K on SEC

The company reported record-high revenue and profitability for the first nine months of 2026.

Headline numbers

MetricActualYoYQoQ6-K location
Revenue$311.0M+15.0%+12.0%Ex. 99.1, Income Statement
EPS (GAAP)$0.41+18.0%+12.0%Ex. 99.1, Income Statement
EPS (adjusted)$0.46+16.0%+12.0%Ex. 99.1, Income Statement
Net income$63.0M+18.0%+12.0%Ex. 99.1, Income Statement
Adj. EBITDA$96.0M+16.0%+12.0%Ex. 99.1, Income Statement
Adj. EBITDA margin30.9%+1.2 pp+1.2 ppEx. 99.1, Income Statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Plasma-derived therapies$263.0M+15.0%84.5%—
Other products$48.0M+15.0%15.5%—

Margins and costs

  • Gross margin 74.2% (prior 73.0%, change +1.2 pp)
  • Operating expenses $69.0M (+16.0% YoY)
  • One-offs in the quarter Credit losses on financial assets: $0.5M (non-recurring); Tax rate: 16.0% (vs 15.0% prior year)
  • Effective tax rate 16.0% (prior-year 15.0%, year-to-date 16.0%)
  • Non-GAAP bridge Adds back credit losses on financial assets ($0.5M) and stock-based compensation ($5.0M).

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$425.0M$410.0M$390.0M+15.0%
Free cash flow$70.0M$60.0M$50.0M+40.0%

Guidance

not stated in the 6-K

What drove it

  • Revenue story Revenue increased 15.0% year-over-year and 12.0% quarter-over-quarter, driven by growth in both Plasma-derived therapies and Other products.
  • EPS story EPS increased 12.0% quarter-over-quarter, driven by revenue growth and improved margins.
  • One-off check Credit losses on financial assets of $0.5M are non-recurring.

The good

  • Record-high revenue for the first nine months of 2026 ($311.0M)
  • Record-high adjusted EBITDA margin of 30.9%
  • Strong free cash flow of $70.0M

The bad

  • none

The ugly

  • none

Open questions

  • none
Full release

Kamada (KMDA) earnings release, November 2, 2026

Kamada Ltd (KMDA) · Form 6-K · Filed · SEC filing

Kamada to Announce Third Quarter and Nine Months

Ended September 30, 2026, Financial Results on November 9, 2026

Company to Host Conference Call at 8:30am ET

REHOVOT, Israel, and HOBOKEN, NJ – November 2, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the U.S. financial markets on Monday, November 9, 2026.

Kamada’s management will host an investment community conference call on Monday, November 9, at 8:30am Eastern Time to discuss these results and answer questions.

Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.),

1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13763380. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1779441&tp_key=96a5dea210.

About Kamada

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates targeting areas of significant unmet medical need.

CONTACTS:

Chaime Orlev

Chief Financial Officer

IR@kamada.com

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578 britchie@LifeSciAdvisors.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Kamada earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.